Corrective Phases R...
Health Care: Drugs
Cellceutix Corporation (CTIX: OTC)
$0.57 0.02 | 3.64%
06/01/12 - 03:58 PM ET
Company Balance Sheet
| Jun 2011 | Jun 2010 | Jun 2009 | Jun 2008 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 68.66K | 3.99K | 140.00K | 351.86K |
| Receivables | 204.14K | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 313.10K | 101.82K | 155.00K | 449.78K |
| Property, Plant & Equipment, Gross | 0.00 | 0.00 | 0.00 | 0.00 |
| Accumulated Depreciation & Depletion | 0.00 | 0.00 | 0.00 | 0.00 |
| Property, Plant & Equipment, Net | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 313.10K | 101.82K | 155.00K | 449.78K |
| Accounts Payable | 2.14M | 1.19M | 340.00K | 13.73K |
| Short Term Debt | 0.00 | 460.00K | 400.00K | 0.00 |
| Other Current Liabilities | 167.10K | 0.00 | 0.00 | 32.31K |
| Total Current Liabilities | 6.77M | 4.90M | 1.95M | 411.77K |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 400.00K |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 833.37K | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 833.37K | 0.00 | 0.00 | 400.00K |
| Total Liabilities | 7.60M | 4.90M | 1.95M | 811.77K |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | -7.29M | -4.80M | -1.79M | -361.99K |
| Common Par | 9.17K | 9.19K | 9.00K | 9.19K |
| Additional Paid In Capital | 4.84M | 631.72K | 203.00K | 148.62K |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -11.38M | -5.44M | -2.00M | -519.80K |
| Treasury Stock | -759.39K | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Capitalization | -7.29M | -4.80M | -1.79M | 38.01K |
| Total Equity | -7.29M | -4.80M | -1.79M | -361.99K |
| Total Liabilities & Stock Equity | 313.10K | 101.82K | 155.00K | 449.78K |
| Total Common Shares Outstanding | 87.58M | 91.94M | 91.84M | 91.89M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 4.14M | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 90.30M | 91.86M | 91.84M | 52.37M |
| Diluted Weighted Shares Outstanding | 90.30M | 91.86M | 91.84M | 52.37M |
| Number of Employees | 2 | 3 | 3 | NA |
| Number of Part-Time Employees | 0 | 0 | 0 | NA |
Portfolios with CTIX
- Portfolio NameUser Type
Latest CTIX Headlines from TheStreet
- Cheap Tickets Up as Cendant Extends Share Offer Deadline 09.24.01 | 08:09 am
- Cheap Tickets Tumbles on Warning 06.26.01 | 11:06 am
- The Daily Interview: Online Travel Skies Getting Crowded 06.13.01 | 10:06 am
- Ticker-Tape Parade: Cendant Buys Cheap Tickets, Semis Get an Upgrade 12.31.69 | 07:12 pm
- Cheap Tickets Leaps on Offer From Cendant 12.31.69 | 07:12 pm
Press Releases for CTIX
- Cellceutix CEO, Leo Ehrlich, Conducts Interview With "Biotech Stock Trader"; Dr. Paul Ginsberg, (Renowned Patent Attorney) Joins Cellceutix Advisory Board - PR Newswire 04.18.11 | 07:04 am
- Cellceutix Poster Presentation On Its P53 Cancer Breakthrough Attracts Wide Interest At 102nd AACR Meeting - PR Newswire 04.11.11 | 06:04 am
- Cellceutix Cancer Drug, Kevetrinâ¢, Shows Increased Levels Of P21; Biomarker For Cancer Trials - PR Newswire 03.31.11 | 08:03 am
- Cellceutix Announces That It Has Signed Confidential Disclosure Agreement For Its Autism Drug With Large Pharmaceutical Company - PR Newswire 03.28.11 | 07:03 am
- Cellceutix Anti-Cancer Breakthrough Selected For Poster Presentation At American Association For Cancer Research (AACR) - PR Newswire 03.21.11 | 07:03 am
- Cellceutix Reports Production Of Its Anti-Cancer Drug Kevetrin⢠Has Begun - PR Newswire 03.14.11 | 06:03 am
- Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company - PR Newswire 03.08.11 | 04:03 pm
- Cellceutix Discovers Drug Activates 'Guardian Angel P53' In Fight Against Leukemia - PR Newswire 03.07.11 | 07:03 am
- Cellceutix Cancer Drug Kevetrin⢠Shows No Genotoxicity In Study - PR Newswire 03.02.11 | 07:03 am
Partner Headlines for CTIX
